Farshad Ahadian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Farshad Ahadian has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Alexios G. Carayannopoulos
Department of Physical Medicine and Rehabilitation, Rhode Island Hospital, Brown University Medical School, Providence, RI, USA
1 shared publication - Ananya Rajan
Department of Bioengineering, University of California, San Diego, La Jolla, USA
1 shared publication - Antoine G. Tohmeh
MultiCare Neurosurgery and Spine, Spokane, USA
1 shared publication - Ashish Gulve
Department of Anesthesiology and Pain Management, James Cook University Hospital, Middlesbrough TS4 3BW, UK
1 shared publication - Bruce Mitchell
Metro Pain Group, Melbourne, Australia
1 shared publication - Capalina Melentyev
Department of Bioengineering, University of California, San Diego, La Jolla, USA
1 shared publication
Latest Publications
- Open Access
- 28 May 2024
- Published by Springer Nature in Microsystem Technologies
- Vol. 31 (5) , 1137-1145
A low-cost, open-source-based optical surgical navigation system using stereoscopic vision
Computer-assisted surgical navigation systems have gained popularity in surgical procedures that demand high amounts of precision. These systems aim to track the real-time positioning of surgical instruments in relation to anatomical structures. Typically, state-of-the-art methods involve tracking reflective 3D marker spheres affixed to both surgical instruments and patient anatomies with infrared cameras. However, these setups are expensive and financially impractical for small healthcare facilities. This study suggests that a fully optical navigation approach utilizing low-cost, off-the-shelf parts may become a viable alternative. We develop a stereoscopic camera setup, costing around $120, to track and monitor the translational movement of open-source based fiducial markers on a positioning platform. We evaluate the camera setup based on its reliability and accuracy. Using the optimal set of parameters, we were able to produce a root mean square error of 2 mm. These results demonstrate the feasibility of real-time, cost-effective surgical navigation using off-the-shelf optical cameras.
- 28 May 2024
- Published by Springer Nature in Microsystem Technologies
- Vol. 31 (5) , 1137-1145
Open AccessA low-cost, open-source-based optical surgical navigation system using stereoscopic vision
Computer-assisted surgical navigation systems have gained popularity in surgical procedures that demand high amounts of precision. These systems aim to track the real-time positioning of surgical instruments in relation to anatomical structures. Typically, state-of-the-art methods involve tracking reflective 3D marker spheres affixed to both surgical instruments and patient anatomies with infrared cameras. However, these setups are expensive and financially impractical for small healthcare facilities. This study suggests that a fully optical navigation approach utilizing low-cost, off-the-shelf parts may become a viable alternative. We develop a stereoscopic camera setup, costing around $120, to track and monitor the translational movement of open-source based fiducial markers on a positioning platform. We evaluate the camera setup based on its reliability and accuracy. Using the optimal set of parameters, we were able to produce a root mean square error of 2 mm. These results demonstrate the feasibility of real-time, cost-effective surgical navigation using off-the-shelf optical cameras.
- Open Access
- 26 December 2023
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 25 (1) , 1-2
President’s Message
Dear Esteemed Members of the American Academy of Pain Medicine,
- 26 December 2023
- Published by Oxford University Press (OUP) in Pain Medicine
- Vol. 25 (1) , 1-2
Open AccessPresident’s Message
Dear Esteemed Members of the American Academy of Pain Medicine,
- Open Access
- 9 March 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (10) , 2486-2498
An implantable restorative-neurostimulator for refractory mechanical chronic low back pain: a randomized sham-controlled clinical trial
Chronic low back pain can be caused by impaired control and degeneration of the multifidus muscles and consequent functional instability of the lumbar spine. Available treatment options have limited effectiveness and prognosis is unfavorable. We conducted an international randomized, double-blind, sham-controlled trial at 26 multidisciplinary centers to determine safety and efficacy of an implantable, restorative neurostimulator designed to restore multifidus neuromuscular control and facilitate relief of symptoms (clinicaltrials.gov identifier: NCT02577354). Two hundred four eligible participants with refractory mechanical (musculoskeletal) chronic LBP and a positive prone instability test indicating impaired multifidus control were implanted and randomized to therapeutic (N = 102) or low-level sham (N = 102) stimulation of the medial branch of the dorsal ramus nerve (multifidus nerve supply) for 30 minutes twice daily. The primary endpoint was the comparison of responder proportions (≥30% relief on the LBP visual analogue scale without analgesics increase) at 120 days. After the primary endpoint assessment, participants in the sham-control group switched to therapeutic stimulation and the combined cohort was assessed through 1 year for long-term outcomes and adverse events. The primary endpoint was inconclusive in terms of treatment superiority (57.1% vs 46.6%; difference: 10.4%; 95% confidence interval, −3.3% to 24.1%, P = 0.138). Prespecified secondary outcomes and analyses were consistent with a modest but clinically meaningful treatment benefit at 120 days. Improvements from baseline, which continued to accrue in all outcome measures after conclusion of the double-blind phase, were clinically important at 1 year. The incidence of serious procedure- or device-related adverse events (3.9%) compared favorably with other neuromodulation therapies for chronic pain.
- 9 March 2021
- Published by Wolters Kluwer Health in Pain
- Vol. 162 (10) , 2486-2498
Open AccessAn implantable restorative-neurostimulator for refractory mechanical chronic low back pain: a randomized sham-controlled clinical trial
Chronic low back pain can be caused by impaired control and degeneration of the multifidus muscles and consequent functional instability of the lumbar spine. Available treatment options have limited effectiveness and prognosis is unfavorable. We conducted an international randomized, double-blind, sham-controlled trial at 26 multidisciplinary centers to determine safety and efficacy of an implantable, restorative neurostimulator designed to restore multifidus neuromuscular control and facilitate relief of symptoms (clinicaltrials.gov identifier: NCT02577354). Two hundred four eligible participants with refractory mechanical (musculoskeletal) chronic LBP and a positive prone instability test indicating impaired multifidus control were implanted and randomized to therapeutic (N = 102) or low-level sham (N = 102) stimulation of the medial branch of the dorsal ramus nerve (multifidus nerve supply) for 30 minutes twice daily. The primary endpoint was the comparison of responder proportions (≥30% relief on the LBP visual analogue scale without analgesics increase) at 120 days. After the primary endpoint assessment, participants in the sham-control group switched to therapeutic stimulation and the combined cohort was assessed through 1 year for long-term outcomes and adverse events. The primary endpoint was inconclusive in terms of treatment superiority (57.1% vs 46.6%; difference: 10.4%; 95% confidence interval, −3.3% to 24.1%, P = 0.138). Prespecified secondary outcomes and analyses were consistent with a modest but clinically meaningful treatment benefit at 120 days. Improvements from baseline, which continued to accrue in all outcome measures after conclusion of the double-blind phase, were clinically important at 1 year. The incidence of serious procedure- or device-related adverse events (3.9%) compared favorably with other neuromodulation therapies for chronic pain.